{
    "organizations": [],
    "uuid": "0146c0f5da5584806337495792e6211b33149947",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-kineret-approved-by-eu-for-treatme/brief-kineret-approved-by-eu-for-treatment-of-stills-disease-idUSFWN1RO06K",
    "ord_in_thread": 0,
    "title": "BRIEF-Kineret approved by EU for treatment of Still's disease",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 11 (Reuters) - Swedish Orphan Biovitrum AB (publ) :\n* KINERET® (ANAKINRA) APPROVED IN THE EU FOR THE TREATMENT OF STILL’S DISEASE\n* SAYS EU HAS APPROVED AN EXTENSION OF THE INDICATION FOR KINERET (ANAKINRA) TO INCLUDE THE TREATMENT OF STILL’S DISEASE, INCLUDING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) AND ADULT-ONSET STILL’S DISEASE (AOSD), IN ALL 28 EUROPEAN UNION (EU) MEMBER STATES. Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)\n ",
    "published": "2018-04-11T15:03:00.000+03:00",
    "crawled": "2018-04-12T14:02:46.032+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "swedish",
        "orphan",
        "biovitrum",
        "ab",
        "publ",
        "anakinra",
        "approved",
        "eu",
        "treatment",
        "still",
        "disease",
        "say",
        "eu",
        "approved",
        "extension",
        "indication",
        "kineret",
        "anakinra",
        "include",
        "treatment",
        "still",
        "disease",
        "including",
        "systemic",
        "juvenile",
        "idiopathic",
        "arthritis",
        "sjia",
        "still",
        "disease",
        "aosd",
        "european",
        "union",
        "eu",
        "member",
        "state",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "stockholm",
        "newsroom"
    ]
}